TY - JOUR
T1 - Treatment of locally advanced esophageal carcinoma
T2 - ASCO guideline
AU - Shah, Manish A.
AU - Kennedy, Erin B.
AU - Catenacci, Daniel V.
AU - Deighton, Dana C.
AU - Goodman, Karyn A.
AU - Malhotra, Narinder K.
AU - Willett, Christopher
AU - Stiles, Brendon
AU - Sharma, Prateek
AU - Tang, Laura
AU - Wijnhoven, Bas P.L.
AU - Hofstetter, Wayne L.
N1 - Publisher Copyright:
© 2020 by American Society of Clinical Oncology.
PY - 2020/8
Y1 - 2020/8
N2 - PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with locally advanced esophageal cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the more recently published literature (1999-2019) on therapy options for patients with locally advanced esophageal cancer and provide recommended care options for this patient population. RESULTS Seventeen randomized controlled trials met the inclusion criteria. Where possible, data were extracted separately for squamous cell carcinoma and adenocarcinoma. RECOMMENDATIONS Multimodality therapy for patients with locally advanced esophageal carcinoma is recommended. For the subgroup of patients with adenocarcinoma, preoperative chemoradiotherapy or perioperative chemotherapy should be offered. For the subgroup of patients with squamous cell carcinoma, preoperative chemoradiotherapy or chemoradiotherapy without surgery should be offered. Additional subgroup considerations are provided to assist with implementation of these recommendations. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
AB - PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with locally advanced esophageal cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the more recently published literature (1999-2019) on therapy options for patients with locally advanced esophageal cancer and provide recommended care options for this patient population. RESULTS Seventeen randomized controlled trials met the inclusion criteria. Where possible, data were extracted separately for squamous cell carcinoma and adenocarcinoma. RECOMMENDATIONS Multimodality therapy for patients with locally advanced esophageal carcinoma is recommended. For the subgroup of patients with adenocarcinoma, preoperative chemoradiotherapy or perioperative chemotherapy should be offered. For the subgroup of patients with squamous cell carcinoma, preoperative chemoradiotherapy or chemoradiotherapy without surgery should be offered. Additional subgroup considerations are provided to assist with implementation of these recommendations. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
UR - http://www.scopus.com/inward/record.url?scp=85089206653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089206653&partnerID=8YFLogxK
U2 - 10.1200/JCO.20.00866
DO - 10.1200/JCO.20.00866
M3 - Review article
C2 - 32568633
AN - SCOPUS:85089206653
SN - 0732-183X
VL - 38
SP - 2677
EP - 2694
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 23
ER -